Clinical trials: Non-erosive Reflux Disease
Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis
This study aims to evaluate the Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects with Healed Erosive Esophagitis
- Trial name
- NCT07732075
- Testing
- JP-1366 10 mg, Lansoprazole 15mg
- Volunteers
- 384 people
- Sponsor
- Onconic Therapeutics Inc.
Non-erosive Gastroesophageal Reflux Disease
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease
This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD
- Trial name
- NCT07160790
- Volunteers
- 321 people
- Sponsor
- Onconic Therapeutics Inc.
Erosive Esophagitis
Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)
A randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of YYD601 in ERD patients (phase 3).
- Trial name
- NCT03943992
- Testing
- YYD601 40mg, Nexium 40mg
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Non-erosive Reflux Disease
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.
- Trial name
- NCT00259077
- Testing
- Omeprazole
- Where
- 26 sites in Japan
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Non-erosive Reflux Disease
Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients
Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients
- Trial name
- NCT03967886
- Testing
- YYD601 20mg, Nexium 20mg
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Non-erosive Reflux Disease
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease
The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4
- Trial name
- NCT02556021
- Testing
- CJ-12420 50mg, CJ-12420 100mg
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- HK inno.N Corporation
Gastroesophageal Reflux
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents.
- Trial name
- NCT00141960
- Testing
- Famotidine
- Where
- 7 sites in Japan
- Volunteers
- 480 people
- Sponsor
- Astellas Pharma Inc
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251758
- Testing
- Dexlansoprazole MR
- Where
- 99 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg, 20 mg, and 40 mg On-Demand) compared to placebo (On-Demand) in relief of episodic heartburn over 6 weeks in participants with symptomatic…
- Trial name
- NCT04799158
- Testing
- Vonoprazan
- Where
- 63 sites in United States
- Volunteers
- 458 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
GERD
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
The aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension…
- Trial name
- PAMES 0109 (NCT01132638)
- Testing
- Magnesium Pantoprazole, Magnesium Esomeprazole
- Where
- 9 sites in Brazil
- Volunteers
- 713 people
- Sponsor
- Takeda